isoobtusilactone A: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6442492 |
| CHEMBL ID | 490165 |
| CHEBI ID | 172537 |
| MeSH ID | M0511702 |
| Synonym |
|---|
| CHEBI:172537 |
| 56522-15-7 |
| (3z,4s)-4-hydroxy-5-methylidene-3-tetradecylideneoxolan-2-one |
| obtusilactone a |
| 2(3h)-furanone, dihydro-4-hydroxy-5-methylene-3-tetradecylidene-, (3z,4s)- |
| isoobtusilactone a |
| (3z,4s)-4-hydroxy-5-methylene-3-tetradecylidene-tetrahydrofuran-2-one |
| CHEMBL490165 |
| (s)-4,5-dihydro-4-hydroxy-5-methylene-3-((z)-tetradecan-1-ylidene)furan-2(3h)-one |
| obtusilactone b |
| (s)-4,5-dihydro-4-hydroxy-5-methylene-3-[(z)-tetradecan-1-ylidene]furan-2(3h)-one |
| DTXSID401154212 |
| (3z,4s)-dihydro-4-hydroxy-5-methylene-3-tetradecylidene-2(3h)-furanone |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Isoobtusilactone A-treated cells also displayed transient increase of ROS during the earlier stage of the experiment, followed by the disruption of mitochondrial transmembrane potential (DeltaPsi(m))." | ( Isoobtusilactone A-induced apoptosis in human hepatoma Hep G2 cells is mediated via increased NADPH oxidase-derived reactive oxygen species (ROS) production and the mitochondria-associated apoptotic mechanisms. Chen, CH; Chen, CY; Cheng, JT; Chern, CL; Liu, TZ; Shih, MK; Wu, CC; Wu, MJ; Yiin, SJ, 2007) | 2.5 |
| Class | Description |
|---|---|
| oxolanes | Any oxacycle having an oxolane (tetrahydrofuran) skeleton. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID468305 | Cytotoxicity against human LNCAP cells after 72 hrs by XTT assay | 2009 | Journal of natural products, Oct, Volume: 72, Issue:10 | Cytotoxic compounds from the stems of Cinnamomum tenuifolium. |
| AID338793 | Toxicity in Artemia salina | 1992 | Journal of natural products, Jan, Volume: 55, Issue:1 | Biologically active gamma-lactones and methylketoalkenes from Lindera benzoin. |
| AID338801 | Insecticidal activity against Aphis gossypii assessed as mortality at 12 ppm | 1992 | Journal of natural products, Jan, Volume: 55, Issue:1 | Biologically active gamma-lactones and methylketoalkenes from Lindera benzoin. |
| AID338796 | Cytotoxicity against human MCF7 cells | 1992 | Journal of natural products, Jan, Volume: 55, Issue:1 | Biologically active gamma-lactones and methylketoalkenes from Lindera benzoin. |
| AID338795 | Cytotoxicity against human A549 cells | 1992 | Journal of natural products, Jan, Volume: 55, Issue:1 | Biologically active gamma-lactones and methylketoalkenes from Lindera benzoin. |
| AID468304 | Cytotoxicity against human DU145 cells after 72 hrs by XTT assay | 2009 | Journal of natural products, Oct, Volume: 72, Issue:10 | Cytotoxic compounds from the stems of Cinnamomum tenuifolium. |
| AID338800 | Insecticidal activity against Tetranychus urticae assessed as mortality at 12 ppm | 1992 | Journal of natural products, Jan, Volume: 55, Issue:1 | Biologically active gamma-lactones and methylketoalkenes from Lindera benzoin. |
| AID338797 | Cytotoxicity against human HT-29 cells | 1992 | Journal of natural products, Jan, Volume: 55, Issue:1 | Biologically active gamma-lactones and methylketoalkenes from Lindera benzoin. |
| AID338799 | Insecticidal activity against Spodoptera eridania assessed as mortality at 12 ppm | 1992 | Journal of natural products, Jan, Volume: 55, Issue:1 | Biologically active gamma-lactones and methylketoalkenes from Lindera benzoin. |
| AID338798 | Insecticidal activity against Diabrotica undecimpunctata assessed as mortality at 12 ppm | 1992 | Journal of natural products, Jan, Volume: 55, Issue:1 | Biologically active gamma-lactones and methylketoalkenes from Lindera benzoin. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.63) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||